Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel

NCT00539968 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00539968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2007
Completion date
December 31, 2009
Enrollment
5 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, lung cancer, ovarian cancer, prostate cancer